Log in

NYSE:LLY - Eli Lilly And Co Stock Price, Forecast & News

$141.12
-0.68 (-0.48 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$140.57
Now: $141.12
$142.32
50-Day Range
$131.14
MA: $138.59
$147.35
52-Week Range
$101.36
Now: $141.12
$147.87
Volume2.27 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio16.11
Dividend YieldN/A
BetaN/A
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP53245710
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees38,680
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.


Eli Lilly And Co (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly And Co's stock symbol?

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly And Co pay dividends? What is the dividend yield for Eli Lilly And Co?

Eli Lilly And Co announced a quarterly dividend on Monday, December 16th. Stockholders of record on Friday, February 14th will be paid a dividend of $0.74 per share on Tuesday, March 10th. This represents a $2.96 annualized dividend and a dividend yield of 2.10%. The ex-dividend date is Thursday, February 13th. This is an increase from Eli Lilly And Co's previous quarterly dividend of $0.65. View Eli Lilly And Co's Dividend History.

How were Eli Lilly And Co's earnings last quarter?

Eli Lilly And Co (NYSE:LLY) released its earnings results on Thursday, January, 30th. The company reported $1.73 earnings per share for the quarter, topping analysts' consensus estimates of $1.52 by $0.21. The firm earned $6.11 billion during the quarter, compared to analysts' expectations of $5.92 billion. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.33 earnings per share. View Eli Lilly And Co's Earnings History.

When is Eli Lilly And Co's next earnings date?

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Eli Lilly And Co.

What guidance has Eli Lilly And Co issued on next quarter's earnings?

Eli Lilly And Co updated its FY20 earnings guidance on Thursday, January, 30th. The company provided EPS guidance of $6.70-6.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.76. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.78 billion.

What price target have analysts set for LLY?

14 analysts have issued twelve-month target prices for Eli Lilly And Co's stock. Their forecasts range from $117.49 to $165.00. On average, they anticipate Eli Lilly And Co's share price to reach $137.95 in the next twelve months. This suggests that the stock has a possible downside of 2.2%. View Analyst Price Targets for Eli Lilly And Co.

What is the consensus analysts' recommendation for Eli Lilly And Co?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eli Lilly And Co.

What are Wall Street analysts saying about Eli Lilly And Co stock?

Here are some recent quotes from research analysts about Eli Lilly And Co stock:
  • 1. According to Zacks Investment Research, "Lilly beat estimates for earnings in the first quarter.  However, Lilly lowered its sales guidance for 2019.  Revenue growth in 2019 is expected to be driven by higher demand for its newer drugs including Trulicity, Jardiance, Taltz, Verzenio and new migraine drug, Emgality as some older drugs like Cialis face generic competition. Lilly has made significant pipeline progress in the past year with several positive late-stage data readouts, multiple approvals and regulatory submissions. Lilly also added promising new pipeline assets through business development deals. The stock has outperformed the industry in the past year. However, competitive pressure on Lilly’s drugs is expected to rise in 2019. Generic competition for several drugs including Cialis, rising pricing pressure, currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line." (5/21/2019)
  • 2. Cantor Fitzgerald analysts commented, ". EPS beat, we maintain our OW rating and 12- month PT of $143. We expect upward earnings revisions to move LLY’s shares higher. This should be driven by sales growth, margin expansion, and pipeline advancements." (4/30/2019)

Has Eli Lilly And Co been receiving favorable news coverage?

News articles about LLY stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Eli Lilly And Co.

Are investors shorting Eli Lilly And Co?

Eli Lilly And Co saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 12,980,000 shares, an increase of 14.8% from the January 15th total of 11,310,000 shares. Based on an average daily trading volume, of 3,450,000 shares, the days-to-cover ratio is presently 3.8 days. Approximately 1.5% of the shares of the stock are sold short. View Eli Lilly And Co's Current Options Chain.

Who are some of Eli Lilly And Co's key competitors?

What other stocks do shareholders of Eli Lilly And Co own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly And Co investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AT&T (T), Intel (INTC), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Bristol-Myers Squibb (BMY), Bank of America (BAC) and Cisco Systems (CSCO).

Who are Eli Lilly And Co's key executives?

Eli Lilly And Co's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 49)
  • Dr. Daniel M. Skovronsky, Sr. VP & Chief Scientific Officer (Age 45)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 56)
  • Mr. Jeffrey N. Simmons, Sr. VP & Pres of Elanco Animal Health (Age 52)

Who are Eli Lilly And Co's major shareholders?

Eli Lilly And Co's stock is owned by a number of of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (11.93%), State Street Corp (3.87%), FMR LLC (1.48%), Bank of New York Mellon Corp (0.85%), Franklin Resources Inc. (0.79%) and Massachusetts Financial Services Co. MA (0.63%). Company insiders that own Eli Lilly And Co stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, Christi Shaw, Daniel Skovronsky, David A Ricks, Donald A Zakrowski, Eli & Co Lilly, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

Which institutional investors are selling Eli Lilly And Co stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., Investec Asset Management LTD, LSV Asset Management, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, AQR Capital Management LLC, Great West Life Assurance Co. Can and DekaBank Deutsche Girozentrale. Company insiders that have sold Eli Lilly And Co company stock in the last year include Aarti S Shah, Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington, Myles O'neill and Stephen F Fry. View Insider Buying and Selling for Eli Lilly And Co.

Which institutional investors are buying Eli Lilly And Co stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Amundi Pioneer Asset Management Inc., Franklin Resources Inc., CI Investments Inc., PGGM Investments, Robeco Institutional Asset Management B.V. and Prudential Financial Inc.. Company insiders that have bought Eli Lilly And Co stock in the last two years include Anne E White, Daniel Skovronsky, David A Ricks, Jackson P Tai and Joshua L Smiley. View Insider Buying and Selling for Eli Lilly And Co.

How do I buy shares of Eli Lilly And Co?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eli Lilly And Co's stock price today?

One share of LLY stock can currently be purchased for approximately $141.12.


MarketBeat Community Rating for Eli Lilly And Co (NYSE LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  993 (Vote Outperform)
Underperform Votes:  811 (Vote Underperform)
Total Votes:  1,804
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly And Co and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel